Misoprostol for Management of Women With an Incomplete Miscarriage
Comparative Study Between Two Doses of Misoprostol in Women With Incomplete First-trimester Miscarriage After Misoprostol Treatment: A Randomized Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Aswan, Egypt, 81528
- Aswan University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women with confirmed incomplete induced miscarriage, less than 12 weeks' gestation.
- No known allergy to misoprostol.
- Women who will be hemodynamically stable.
- Good access to emergency facilities
Exclusion Criteria:
- Women with signs of severe infection ( fever > 38°)
- Women with severe vaginal bleeding
- Women are known to have allergies to prostaglandins
- Severe abdominal pain requiring immediate intervention
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: misoprostol 800 µg
received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
|
received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
|
|
Active Comparator: misoprostol 400 µg
received misoprostol 400 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
|
received misoprostol 400 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The number of patients with complete miscarriage at 1 week
Time Frame: 7 days
|
The number of patients with complete miscarriage at 1 week
|
7 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- aswu/354/7/19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Miscarriage
-
NCT05542797Not yet recruiting
-
NCT03320213CompletedThreatened Miscarriage in First Trimester
-
NCT02401425CompletedComplete Miscarriage
-
NCT02706470UnknownMiscarriage, Recurrent
-
NCT05103098Not yet recruiting
-
NCT05094375Not yet recruiting
-
NCT03065660Completed
-
NCT03309735CompletedThreatened Miscarriage
-
NCT02690129UnknownThreatened Miscarriage
-
NCT04604366Completed
Clinical Trials on misoprostol 800 µg
-
NCT01508143Completed
-
NCT05103098Not yet recruiting
-
NCT05094375Not yet recruiting
-
NCT00386867Completed
-
NCT05491785Completed
-
NCT05260437Completed
-
NCT03834012Withdrawn
-
NCT05420077TerminatedCOVID-19 | Infectious Disease
-
NCT05788185Terminated